Streetbeat News

Regulatory

CKPT

Checkpoint Therapeutics announced its Q3 2024 financial results and updates, highlighting the FDA review of its Biologics License Application for cosibelimab, with a PDUFA goal date set for December 28, 2024.

Portfolio Pulse from

November 12, 2024 | 9:45 pm

NOVA

QS

SEDG

QuantumScape, SolarEdge, and Sunnova Energy saw significant stock declines due to uncertainty around clean energy incentives and rising interest rates, impacting investor sentiment negatively.

Portfolio Pulse from

November 12, 2024 | 9:45 pm

PBM

Psyence Biomedical Ltd. announced the results of its annual and special general meeting, including a share consolidation and receipt of an additional staff determination from Nasdaq.

Portfolio Pulse from

November 12, 2024 | 9:45 pm

INAB

IN8bio, Inc. (Nasdaq: INAB) reported its Q3 2024 financial results, highlighting that all Acute Myeloid Leukemia patients in the INB-100 trial remain in complete remission. The company received FDA guidance for a future trial and closed a private placement for $11.6 million, extending its cash runway through 2025.

Portfolio Pulse from

November 12, 2024 | 9:45 pm

ENSC

Ensysce Biosciences reported its Q3 2024 financial results, highlighting a $14 million NIH grant and progress in clinical trials for its PF614-MPAR therapy. The company also submitted a Phase 3 protocol to the FDA.

Portfolio Pulse from

November 12, 2024 | 9:30 pm

HTOO

NDAQ

Fusion Fuel Green PLC received a Staff Determination Notice from Nasdaq for not meeting the minimum stockholders' equity requirement for continued listing. The company has submitted an appeal request.

Portfolio Pulse from

November 12, 2024 | 9:30 pm

CRNX

Crinetics Pharmaceuticals is set to present its advancements in neuroendocrine tumor treatments at the NANETS Annual Meeting. The company will debut its novel nonpeptide drug conjugate platform, highlighting the preclinical profile of its lead candidate, CRN09682, which targets SST2-expressing tumors and is expected to submit an IND by early 2025.

Portfolio Pulse from

November 12, 2024 | 9:30 pm

BHVN

Biohaven Ltd. reported its Q3 2024 financial results, highlighting $642 million in cash and securities. The company achieved positive trial results for troriluzole in spinocerebellar ataxia, with plans for an NDA re-submission. Biohaven is advancing multiple drug programs, including taldefgrobep alfa for spinal muscular atrophy and obesity, and BHV-2100 for migraine and neuropathic pain.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

QTRX

Quanterix Corporation announced preliminary financial results for Q3 2024 and reaffirmed its full-year guidance. The company will restate certain prior period financial statements due to non-cash errors.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

CLYM

Climb Bio announced its Q3 2024 financial results and business updates, including the appointment of Douglas Williams, Ph.D. as Chair of the Board, FDA clearance for an IND for systemic lupus erythematosus, and the addition of Gary Hao, Ph.D. to the management team.

Portfolio Pulse from

November 12, 2024 | 9:15 pm